Andrew M. Tager, M.D., Pulmonary and Critical Care Unit and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School


Dr. Andrew Tager is a physician-scientist in the Pulmonary and Critical Care Unit, and the Center for Immunology and Inflammatory Diseases, at the Massachusetts General Hospital, an Associate Professor in Medicine at Harvard Medical School, and an Associate Faculty Member of the Ragon Institute of MGH, MIT and Harvard. Dr. Tager received his M.D. from Harvard Medical School and completed both his internal medicine residency and his pulmonary and critical care medicine fellowship at the MGH. Dr. Tager began his own laboratory after his post-doctoral research training in the laboratory of Dr. Andrew Luster, also at the MGH. Dr. Tager’s laboratory focuses on two separate areas of investigation, (1) the pathogenesis of idiopathic pulmonary fibrosis, scleroderma and other fibrotic diseases, focusing on bioactive lipid mediators, (2) and anti-HIV immunity, using an improved humanized mouse model of HIV infection.

Mervyn J. Turner, PhD, Bay City Capital

Dr. Mervyn Turner has over 25 years of experience in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets, strategy development and implementation. In his last role prior to his retirement from Merck & Co. Inc., he was the company's first Chief Strategy Officer and drove strategy planning and resource planning discussions. He also worked with the research division, the commercial organization and the manufacturing division to develop a coherent, overarching strategy for Merck & Co. Inc.'s investments in the emerging markets. Prior to that, he was head of World Wide Licensing & External Research and was personally involved in more than 200 strategic transactions, including mergers and acquisitions. Dr. Turner has published over 80 articles in peer-reviewed journals.

Stephen Gately, Ph.D., President and CSO of TD2

Dr. Gately obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital. Thereafter he joined the Department of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine as Research Assistant Professor where his research focused on the identification and development of pharmacologic and endogenous inhibitors of angiogenesis. He then joined the oncology-focused biopharmaceutical company NeoPharm where he served as Executive Director of Translational Medicine. In this position Dr. Gately had responsibility for the design and implementation of basic and clinical research studies to enhance the scientific understanding and positioning of existing products and development candidates. Dr. Gately then served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the scientific integration of non-clinical, clinical and regulatory data on portfolio compounds for optimal commercial planning. Dr. Gately is currently President and Chief Scientific Officer at Translational Drug Development (TD2).

Jilly F. Evans, Ph.D.

Dr. Jilly Evans is a co-founder of PharmAkea Inc and currently is a member of the SAB. From June 2011 to June 2012 she was an internal consultant at Celgene San Diego, and prior to that Dr Evans was a co-founder and head of Biology of Amira Pharmaceuticals Inc. Dr. Evans spent 23 years with Merck Research Laboratories where she was Director of Pharmacology. During her tenure with Merck, she led the orphan GPCR group and was a key biologist on both the Singulair and Vioxx teams. She also contributed to the development of several clinical stage compounds one of which (MK0591) completed Phase II. Dr. Evans completed her BSc and MSc (1st class Hons) at Auckland University and obtained a Ph.D. in biochemistry at The University of British Columbia, Vancouver. She is an inventor on several biological patents and is a co-author on over 130 peer-reviewed published papers. Dr. Evans is a recognised international authority on leukotriene and eicosanoid biochemistry and builder of drug development teams. For her contributions to drug development and science education she was made an Honorary Fellow of the Royal Society of New Zealand (FRSNZ (Hon) and has been named one of the 2013 distinguished alumni of Auckland University.